Consequent to the above allotment, the paid up share capital of the company has gone up from 31,53,90,630 equity shares of Rs 2 each, aggregating Rs 63,07,81,260, to 31,54,00,630 equity shares of Rs 2 each, aggregating Rs 63,08,01,260.
Suven Pharmaceuticals has notified the BSE that its board had decided to increase the FII investment limit to 40 per cent and split the Rs 10 paid up equity shares into five shares of face value Rs 2 each.
Suven said its board had also approved an issue not exceeding 10,00,000 equity shares at a price not less than price as calculated as per Sebi guidelines on preferential offers to FII/banks/bodies corporate/financial institutions or its nominees or affiliates.
